Beginning to sound desperate Indian God. |
Everybody who have listened to them are losing money |
No one is buying this carp. You would do well to stay away imo.
Stay away
Stay clear
Save lives. |
Hazl and Z1CO will surely be investigated |
False rise for the placing. Get out NOW |
Gone NT to buy 100,000 @ 2.25p |
The pdfile siko and pdfile machines been busy in Rochdale |
Share's are seriously under valued 4p to 5p fair value |
Lot's of bio/pharma's stocks have done exceptionally well so far in 2025 , GDR shares could easily RISE by 100% , 200% ... over the coming days/weeks. |
C'mon GDR, GLA |
Indeed.
Thanks for the reminders. |
It's just a matter of time before MT-RNR1 ID Kit is rolled out nationally in the UK , starting with NHS Scotland. |
genedrive
4,379 followers
1h
👶 Using our rapid genetic test, the Neonatal Unit at Bolton NHS Foundation Trust were empowered with the information to make a quick prescription change, that potentially saved a baby's hearing.
💊 Prescribing the standard antibiotic would likely have resulted in lifelong hearing loss and a very different future for this baby and their family - due to the genetic variant they carried.
👏 What a fantastic result! |
Beeks , i still feel that GDR with it's unique test MT-RNR1 ID Kit will get taken over at a substantial premium to the current price. |
The company is seriously undervalued compared to some of other bio/pharma companies on the AIM.
GDR has two world class approved by NICE and they are being used by the NHS hospitals to save lives and in the process will save the NHS £millions. |
All good Sir! I spotted you living the dream on some other minnows since the new year :)As I've said previously, you are very good at this game!Looking forward to this going Northwards. |
Hiya beeks
Very well thanks and yourself ? |
Morning Z1co. Hope you are well. |
 January 27, 2025
First neonatal baby avoids lifelong hearing loss thanks to ground-breaking gene test
A baby receiving care in Bolton’s Neonatal Unit has benefitted from a ground-breaking test
Genedrive rapidly tests whether babies could go deaf after being given certain antibiotics
November 2024 saw the first positive test come back allow for a change in prescription
A baby receiving care in Royal Bolton Hospital’s Neonatal Unit has become the first to benefit from a ground-breaking gene test which aims to prevent lifelong hearing loss.
Royal Bolton was one of the first hospitals to go live with the cutting edge Genedrive System, which uses a cheek swab to rapidly detect potential genetic mutations which can cause permanent hearing loss in babies when they are given aminoglycoside antibiotics.
The system means babies admitted to the Neonatal Intensive Care Unit with sepsis are rapidly tested and given an alternative antibiotic if they are positive, avoiding a lifetime of deafness.
In November 2024, the programme saw its first instance where a positive test came back, allowing for a change of planned prescribed antibiotics.
Jamie Osborne, Principal Biochemist and Point of Care Testing Clinical Lead at Bolton NHS Foundation Trust, said:
Advancements in technology are enabling us to drastically transform the care we’re able to provide to some of our most vulnerable patients.
“These interventions are already helping our babies avoid lifelong hearing loss, transforming the lives of patients and their families.
“We’re incredibly proud of the technology and that Bolton is amongst the first sites in the world to adopt it. The work we’re doing here will be critical to ongoing technology assessments by the National Institute for Health and Care Excellence.
The Genedrive System, funded as a pilot study by Health Innovation Manchester, was developed in partnership with Manchester University NHS Foundation Trust. |
What a success we will become.
Amazing story |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
